(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters

@article{Rothman2003FenfluramineAI,
  title={(+)-Fenfluramine and Its Major Metabolite, (+)-Norfenfluramine, Are Potent Substrates for Norepinephrine Transporters},
  author={R. Rothman and R. D. Clark and J. Partilla and M. Baumann},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2003},
  volume={305},
  pages={1191 - 1199}
}
(±)-Fenfluramine is an amphetamine analog that was once widely prescribed as an appetite suppressant. Although (±)-fenfluramine is no longer clinically available, the mechanisms underlying its anorectic properties are still of interest. Upon peripheral administration, stereoisomers of (±)-fenfluramine are N-deethylated to form the metabolites, (+)- and (-)-norfenfluramine. It is well accepted that isomers of (±)-fenfluramine and (±)-norfenfluramine interact with 5-hydroxytryptamine (serotonin… Expand
(+)-Norfenfluramine-Induced Arterial Contraction Is Not Dependent on Endogenous 5-Hydroxytryptamine or 5-Hydroxytryptamine Transporter
(+)-Norfenfluramine, the major metabolite of fenfluramine, causes vasoconstriction dependence on the 5-hydroxytryptamine (5-HT)2A receptor in rat. (+)-Norfenfluramine was reported as aExpand
The Fenfluramine Metabolite (+)-Norfenfluramine Is Vasoactive
TLDR
It is demonstrated for the first time that (+)-norfenfluramine is vasoactive and has the potential to increase blood pressure. Expand
Evidence for a Role of Transporter-Mediated Currents in the Depletion of Brain Serotonin Induced by Serotonin Transporter Substrates
TLDR
Comparisons of the pharmacology of several SERT substrates confirmed that drug-induced 5-HT release probably does not mediate 5- HT depletion, however, the magnitude of transporter-mediated inward current may be a critical factor in the cascade of events leading to5-HT deficits. Expand
Relationship between anorexia and loss of serotonin uptake sites in brain of mice and rats receiving d-norfenfluramine or d-fenfluramine
TLDR
It is shown in mice that D-F causes a greater loss of 5-HT uptake than D-NF, and that at the lowest dose regimen used uptake was unaffected in rats but was reduced in mice, and the data are discussed in terms of the species difference in behavioral tolerance and differences in neurochemical profile. Expand
The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain.
TLDR
The results suggest that some designer drugs strongly act on the central nerve system to the same extent as restricted drugs. Expand
Amphetamine-like Neurochemical and Cardiovascular Effects of α-Ethylphenethylamine Analogs Found in Dietary Supplements
TLDR
The results show that α-ethylphenethylamine analogs are biologically active, and although less potent than amphetamine, they produce cardiovascular effects that could pose risks to humans. Expand
2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors
TLDR
2-AI is predicted to have (+)-amphetamine-like effects and abuse potential whereas the ring-substituted derivatives may produce 3,4-methylenedioxymethamphetamine (MDMA)-like effects but with less abuse liability. Expand
A Serotonin and Melanocortin Circuit Mediates d-Fenfluramine Anorexia
TLDR
The results identify a neurochemically defined neural circuit through which d-Fen influences appetite and indicate that this 5-HT2CR/POMC-MC4R/SIM1 circuit may yield a more refined target to exploit for weight loss. Expand
Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
TLDR
The results show that (+-FFA, (−)-FFA and (+)-norFFA displayed significant antiepileptic effects in the preclinical model, and thus can be considered as compounds actively contributing to the clinical efficacy of FFA. Expand
N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability
TLDR
Converging lines of evidence show that lengthening the N-alkyl substituent of 4-MA reduces potency to inhibit transporters, eliminates substrate activity at DAT and NET, and decreases abuse liability of the compounds. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Therapeutic and adverse actions of serotonin transporter substrates.
TLDR
New medications can be developed that selectively release 5-HT without increasing the risk for adverse effects of valvular heart disease, PPH, and neurotoxicity, as well as useful for treating a variety of psychiatric disorders. Expand
Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors
TLDR
The present series of studies provide unequivocal evidence for an important role of the 5-HT2C receptor in the mediation of d-fenfluramine and d-norfen fluramine-induced hypophagia in the rat and do not support the involvement of 5- HT1A/1B/2A/2B receptors. Expand
1-(m-Chlorophenyl)piperazine (mCPP) Dissociates In Vivo Serotonin Release from Long-Term Serotonin Depletion in Rat Brain
TLDR
The notion that 5- HT release per se may not be sufficient to produce the long-term 5-HT deficits associated with d-fenfluramine and other amphetamines is supported. Expand
Indan Analogs of Fenfluramine and Norfenfluramine Have Reduced Neurotoxic Potential
TLDR
It is demonstrated that incorporation of the side-chain of phenylisopropylamines into the five-membered ring of a 2-aminoindan changes both the molecular pharmacology and the neurotoxic profile of FEN and norFEN, but does not diminish the drugs' ability to reduce body weight. Expand
In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia.
TLDR
The results show that d-F is a potent 5-HT releaser also in the hypothalamus, one major site of action of the anorexigenic drug. Expand
d-Fenfluramine- and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors.
Severe depletion of 5-hydroxytryptamine (5-HT) by para-chlorophenylalanine (pCPA, 150 mg/kg per day x3) did not alter the hypophagic effect of d-fenfluramine (1-3 mg/kg i.p.) 1 h after foodExpand
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
TLDR
Using microdialysis in the hypothalamus of unanesthetized rats, evidence is provided that serotonin- (5-HT) selective and nonselective reuptake inhibitors can be distinguished from the 5-HT-releasing agent fenfluramine by four criteria. Expand
Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications
TLDR
It is suggested that all clinically available medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors and that clinicians should consider suspending their use of medications with significant activity at5-HT1B receptors. Expand
Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.
TLDR
It is speculated that medications that are 5-HT transporter substrates get translocated into pulmonary cells where, depending on the degree of drug retention, their intrinsic drug toxicity, and individual susceptibility, PPH could develop as a response to high levels of these drugs or metabolites. Expand
Comparison of the effects of repeated oral versus subcutaneous fenfluramine administration on rat brain monoamine neurons: Pharmacokinetic and dose-response data
TLDR
The importance of norfenfluramine levels in the brain in determining the high-dose neurotoxic effects of fenfluramines on brain 5-HT neurons in rats is suggested. Expand
...
1
2
3
4
5
...